跳到正文
原文
Endpoints News 生物医药· Kyle LaHucik·· 2026-10-01AI 评分27

Eli Lilly 终止合作,Foghorn 裁员 40%

Lilly pulls back from Foghorn's synthetic lethality work as biotech sheds 40% of staff

AI 导读

Eli Lilly 宣布放弃 Foghorn Therapeutics 的“合成致死”药物开发项目,Foghorn 因此将裁员 40%。该决定导致这家生物技术公司大幅缩减人员,凸显了双方在药物研发路径上的最终分道扬镳。

正文

Eli Lil­ly is walk­ing away from Foghorn Ther­a­peu­tics’ “syn­thet­ic lethal­i­ty” drug de­vel­op­ment, and the small biotech is re­duc­ing its head­count by 40% as a re­sult …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news